Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Cancer remains one of the most formidable challenges in modern medicine, due to its complex and dynamic nature, which demands innovative therapeutic approaches. One major challenge to cancer treatment is the tumour microenvironment and in particular tumour hypoxia (low oxygen levels), which contribu...
Saved in:
Main Author: | Brian M Ortmann |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | BMJ Oncology |
Online Access: | https://bmjoncology.bmj.com/content/3/1/e000154.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE HYPOXIA INDUCIBLE FACTOR (HIF) PATHWAY IN AML: THERAPEUTIC TARGETING
by: Büşra Tuğçe Akman
Published: (2024-12-01) -
Hypoxia-Inducible Factor-1 as a Therapeutic Target in Endometrial Cancer Management
by: Laura M. S. Seeber, et al.
Published: (2010-01-01) -
Hypoxia Inducible Factor Pathway and Physiological Adaptation: A Cell Survival Pathway?
by: Hemant Kumar, et al.
Published: (2015-01-01) -
Atypical chemokine receptor 2 expression is directly regulated by hypoxia inducible factor-1 alpha in cancer cells under hypoxia
by: Alice Benoit, et al.
Published: (2024-11-01) -
Targeting hypoxia inducible factor-1 alpha in rheumatoid arthritis: Rationale, opportunities and challenges
by: George D. Kalliolias, et al.
Published: (2024-12-01)